NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Osmetech’s eSensor Warfarin Sensitivity Test, the London-based firm announced today.
 
The genetic test is used to aid physicians in identifying patients who are at risk for increased sensitivity to the blood-thinning drug warfarin. Osmetech submitted its application with the FDA for the test at the beginning of this year.
 
The firm said that the FDA also cleared its second-generation eSensor XT-8 molecular diagnostics platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.